nodes	percent_of_prediction	percent_of_DWPC	metapath
Procainamide—SCN10A—skin cancer	0.724	1	CbGaD
Procainamide—SLC22A5—Dactinomycin—skin cancer	0.0405	0.735	CbGbCtD
Procainamide—CYP2D6—Vemurafenib—skin cancer	0.0146	0.265	CbGbCtD
Procainamide—SCN11A—nerve—skin cancer	0.00463	0.112	CbGeAlD
Procainamide—SCN8A—nerve—skin cancer	0.00351	0.0849	CbGeAlD
Procainamide—Hepatic enzyme increased—Vismodegib—skin cancer	0.003	0.0272	CcSEcCtD
Procainamide—Electrocardiogram change—Fluorouracil—skin cancer	0.00289	0.0262	CcSEcCtD
Procainamide—SCN10A—nerve—skin cancer	0.00235	0.0568	CbGeAlD
Procainamide—Supraventricular tachycardia—Imiquimod—skin cancer	0.00228	0.0207	CcSEcCtD
Procainamide—Pericarditis—Fluorouracil—skin cancer	0.00191	0.0173	CcSEcCtD
Procainamide—Abdominal pain upper—Vismodegib—skin cancer	0.00188	0.0171	CcSEcCtD
Procainamide—Vasculitis—Vemurafenib—skin cancer	0.0018	0.0163	CcSEcCtD
Procainamide—Drug fever—Docetaxel—skin cancer	0.00179	0.0162	CcSEcCtD
Procainamide—DNMT1—nipple—skin cancer	0.00172	0.0416	CbGeAlD
Procainamide—Lupus erythematosus—Docetaxel—skin cancer	0.0016	0.0145	CcSEcCtD
Procainamide—Rash maculo-papular—Vemurafenib—skin cancer	0.0016	0.0145	CcSEcCtD
Procainamide—Hepatic enzyme increased—Imiquimod—skin cancer	0.00158	0.0144	CcSEcCtD
Procainamide—Proparacaine—SCN10A—skin cancer	0.00144	0.18	CrCbGaD
Procainamide—Hepatomegaly—Dactinomycin—skin cancer	0.0014	0.0127	CcSEcCtD
Procainamide—Atrial fibrillation—Vemurafenib—skin cancer	0.00134	0.0122	CcSEcCtD
Procainamide—Oxybuprocaine—SCN10A—skin cancer	0.00131	0.165	CrCbGaD
Procainamide—Arthritis—Vemurafenib—skin cancer	0.00131	0.0119	CcSEcCtD
Procainamide—Chloroprocaine—SCN10A—skin cancer	0.00122	0.153	CrCbGaD
Procainamide—DNMT1—connective tissue—skin cancer	0.00122	0.0295	CbGeAlD
Procainamide—Dysgeusia—Vismodegib—skin cancer	0.00122	0.011	CcSEcCtD
Procainamide—Procaine—SCN10A—skin cancer	0.00117	0.146	CrCbGaD
Procainamide—Cinchocaine—SCN10A—skin cancer	0.00117	0.146	CrCbGaD
Procainamide—DNMT1—epithelium—skin cancer	0.00116	0.028	CbGeAlD
Procainamide—Atrial fibrillation—Imiquimod—skin cancer	0.00115	0.0104	CcSEcCtD
Procainamide—Arthritis—Imiquimod—skin cancer	0.00112	0.0101	CcSEcCtD
Procainamide—SCN7A—female reproductive system—skin cancer	0.00112	0.0271	CbGeAlD
Procainamide—Cardiac failure—Imiquimod—skin cancer	0.00111	0.0101	CcSEcCtD
Procainamide—Lethargy—Imiquimod—skin cancer	0.00111	0.0101	CcSEcCtD
Procainamide—DNMT1—skin of body—skin cancer	0.0011	0.0266	CbGeAlD
Procainamide—SCN11A—head—skin cancer	0.0011	0.0266	CbGeAlD
Procainamide—Eosinophilia—Vemurafenib—skin cancer	0.00109	0.00989	CcSEcCtD
Procainamide—Systemic lupus erythematosus—Docetaxel—skin cancer	0.00108	0.00977	CcSEcCtD
Procainamide—Arthralgia—Vismodegib—skin cancer	0.00106	0.00959	CcSEcCtD
Procainamide—Myalgia—Vismodegib—skin cancer	0.00106	0.00959	CcSEcCtD
Procainamide—SLC22A4—neck—skin cancer	0.00105	0.0255	CbGeAlD
Procainamide—DNMT1—mammalian vulva—skin cancer	0.001	0.0243	CbGeAlD
Procainamide—SLC22A3—nipple—skin cancer	0.000968	0.0234	CbGeAlD
Procainamide—Hepatic enzyme increased—Temozolomide—skin cancer	0.000948	0.0086	CcSEcCtD
Procainamide—SCN7A—head—skin cancer	0.000934	0.0226	CbGeAlD
Procainamide—Benzocaine—SCN10A—skin cancer	0.000926	0.116	CrCbGaD
Procainamide—Musculoskeletal discomfort—Vismodegib—skin cancer	0.000923	0.00838	CcSEcCtD
Procainamide—Supraventricular tachycardia—Docetaxel—skin cancer	0.00091	0.00826	CcSEcCtD
Procainamide—DNMT1—lymphoid tissue—skin cancer	0.00089	0.0216	CbGeAlD
Procainamide—Decreased appetite—Vismodegib—skin cancer	0.000881	0.00799	CcSEcCtD
Procainamide—DNMT1—female reproductive system—skin cancer	0.000858	0.0208	CbGeAlD
Procainamide—Depression—Imiquimod—skin cancer	0.000835	0.00757	CcSEcCtD
Procainamide—SCN8A—head—skin cancer	0.000832	0.0202	CbGeAlD
Procainamide—Gastrointestinal pain—Vismodegib—skin cancer	0.000829	0.00752	CcSEcCtD
Procainamide—Cardiac disorder—Vemurafenib—skin cancer	0.000818	0.00742	CcSEcCtD
Procainamide—Abdominal pain—Vismodegib—skin cancer	0.000801	0.00727	CcSEcCtD
Procainamide—Hepatic failure—Dactinomycin—skin cancer	0.000801	0.00727	CcSEcCtD
Procainamide—Arthritis—Bleomycin—skin cancer	0.000794	0.0072	CcSEcCtD
Procainamide—Chills—Vemurafenib—skin cancer	0.000791	0.00717	CcSEcCtD
Procainamide—Pleural effusion—Docetaxel—skin cancer	0.000779	0.00707	CcSEcCtD
Procainamide—Lidocaine—SCN10A—skin cancer	0.000755	0.0946	CrCbGaD
Procainamide—Dysgeusia—Vemurafenib—skin cancer	0.000751	0.00681	CcSEcCtD
Procainamide—Rash maculo-papular—Fluorouracil—skin cancer	0.000751	0.00681	CcSEcCtD
Procainamide—Lethargy—Dactinomycin—skin cancer	0.000735	0.00666	CcSEcCtD
Procainamide—Asthenia—Vismodegib—skin cancer	0.000727	0.0066	CcSEcCtD
Procainamide—Hepatic failure—Temozolomide—skin cancer	0.000725	0.00657	CcSEcCtD
Procainamide—DNMT1—head—skin cancer	0.000717	0.0174	CbGeAlD
Procainamide—Pruritus—Vismodegib—skin cancer	0.000717	0.0065	CcSEcCtD
Procainamide—SLC22A5—nipple—skin cancer	0.000704	0.017	CbGeAlD
Procainamide—Flushing—Imiquimod—skin cancer	0.000698	0.00633	CcSEcCtD
Procainamide—Diarrhoea—Vismodegib—skin cancer	0.000693	0.00629	CcSEcCtD
Procainamide—SCN10A—lymphoid tissue—skin cancer	0.000691	0.0167	CbGeAlD
Procainamide—SLC22A3—connective tissue—skin cancer	0.000686	0.0166	CbGeAlD
Procainamide—BCHE—nipple—skin cancer	0.000685	0.0166	CbGeAlD
Procainamide—Chills—Imiquimod—skin cancer	0.000674	0.00612	CcSEcCtD
Procainamide—SCN7A—lymph node—skin cancer	0.000654	0.0158	CbGeAlD
Procainamide—Myalgia—Vemurafenib—skin cancer	0.000653	0.00592	CcSEcCtD
Procainamide—Arthralgia—Vemurafenib—skin cancer	0.000653	0.00592	CcSEcCtD
Procainamide—SCN4A—head—skin cancer	0.000652	0.0158	CbGeAlD
Procainamide—Oliguria—Docetaxel—skin cancer	0.000647	0.00587	CcSEcCtD
Procainamide—Vomiting—Vismodegib—skin cancer	0.000644	0.00585	CcSEcCtD
Procainamide—SCN1A—head—skin cancer	0.000629	0.0152	CbGeAlD
Procainamide—Cardiac failure—Fluorouracil—skin cancer	0.000615	0.00558	CcSEcCtD
Procainamide—Lethargy—Fluorouracil—skin cancer	0.000612	0.00555	CcSEcCtD
Procainamide—SCN3A—female reproductive system—skin cancer	0.000607	0.0147	CbGeAlD
Procainamide—Ill-defined disorder—Imiquimod—skin cancer	0.000607	0.00551	CcSEcCtD
Procainamide—Nausea—Vismodegib—skin cancer	0.000602	0.00546	CcSEcCtD
Procainamide—Angioedema—Imiquimod—skin cancer	0.000598	0.00542	CcSEcCtD
Procainamide—Malaise—Imiquimod—skin cancer	0.00059	0.00535	CcSEcCtD
Procainamide—Hypotension—Vemurafenib—skin cancer	0.000585	0.00531	CcSEcCtD
Procainamide—Neutropenia—Dactinomycin—skin cancer	0.000582	0.00528	CcSEcCtD
Procainamide—SCN2A—head—skin cancer	0.000577	0.014	CbGeAlD
Procainamide—Musculoskeletal discomfort—Vemurafenib—skin cancer	0.00057	0.00517	CcSEcCtD
Procainamide—Cardiac arrest—Fluorouracil—skin cancer	0.00057	0.00517	CcSEcCtD
Procainamide—Convulsion—Imiquimod—skin cancer	0.000567	0.00514	CcSEcCtD
Procainamide—SLC22A3—mammalian vulva—skin cancer	0.000565	0.0137	CbGeAlD
Procainamide—Myalgia—Imiquimod—skin cancer	0.000557	0.00505	CcSEcCtD
Procainamide—Arthralgia—Imiquimod—skin cancer	0.000557	0.00505	CcSEcCtD
Procainamide—SCN10A—head—skin cancer	0.000557	0.0135	CbGeAlD
Procainamide—Discomfort—Imiquimod—skin cancer	0.00055	0.00499	CcSEcCtD
Procainamide—Decreased appetite—Vemurafenib—skin cancer	0.000544	0.00494	CcSEcCtD
Procainamide—Lightheadedness—Docetaxel—skin cancer	0.000534	0.00484	CcSEcCtD
Procainamide—SLC22A4—female reproductive system—skin cancer	0.000532	0.0129	CbGeAlD
Procainamide—Neutropenia—Temozolomide—skin cancer	0.000526	0.00477	CcSEcCtD
Procainamide—Shock—Imiquimod—skin cancer	0.000525	0.00477	CcSEcCtD
Procainamide—Agranulocytosis—Dactinomycin—skin cancer	0.000518	0.0047	CcSEcCtD
Procainamide—Eosinophilia—Fluorouracil—skin cancer	0.000513	0.00466	CcSEcCtD
Procainamide—SCN9A—lymph node—skin cancer	0.000512	0.0124	CbGeAlD
Procainamide—Anorexia—Imiquimod—skin cancer	0.000509	0.00462	CcSEcCtD
Procainamide—SCN3A—head—skin cancer	0.000507	0.0123	CbGeAlD
Procainamide—SCN5A—head—skin cancer	0.000506	0.0123	CbGeAlD
Procainamide—DNMT1—lymph node—skin cancer	0.000502	0.0122	CbGeAlD
Procainamide—Depression—Temozolomide—skin cancer	0.0005	0.00454	CcSEcCtD
Procainamide—Flushing—Bleomycin—skin cancer	0.000496	0.0045	CcSEcCtD
Procainamide—Body temperature increased—Vemurafenib—skin cancer	0.000495	0.00449	CcSEcCtD
Procainamide—Musculoskeletal discomfort—Imiquimod—skin cancer	0.000487	0.00441	CcSEcCtD
Procainamide—SLC22A3—female reproductive system—skin cancer	0.000484	0.0117	CbGeAlD
Procainamide—Hepatic failure—Docetaxel—skin cancer	0.000482	0.00437	CcSEcCtD
Procainamide—Chills—Bleomycin—skin cancer	0.000479	0.00435	CcSEcCtD
Procainamide—Decreased appetite—Imiquimod—skin cancer	0.000464	0.00421	CcSEcCtD
Procainamide—Flushing—Dactinomycin—skin cancer	0.000462	0.00419	CcSEcCtD
Procainamide—Hypersensitivity—Vemurafenib—skin cancer	0.000461	0.00418	CcSEcCtD
Procainamide—Atrial fibrillation—Docetaxel—skin cancer	0.000457	0.00414	CcSEcCtD
Procainamide—Renal impairment—Docetaxel—skin cancer	0.000455	0.00413	CcSEcCtD
Procainamide—SLC22A5—skin of body—skin cancer	0.000451	0.0109	CbGeAlD
Procainamide—Asthenia—Vemurafenib—skin cancer	0.000449	0.00408	CcSEcCtD
Procainamide—Hallucination—Temozolomide—skin cancer	0.000448	0.00407	CcSEcCtD
Procainamide—DNMT1—Regulation of retinoblastoma protein—CDK4—skin cancer	0.000447	0.00722	CbGpPWpGaD
Procainamide—Chills—Dactinomycin—skin cancer	0.000447	0.00405	CcSEcCtD
Procainamide—Cardiac failure—Docetaxel—skin cancer	0.000444	0.00402	CcSEcCtD
Procainamide—Pruritus—Vemurafenib—skin cancer	0.000443	0.00402	CcSEcCtD
Procainamide—Lethargy—Docetaxel—skin cancer	0.000442	0.00401	CcSEcCtD
Procainamide—Feeling abnormal—Imiquimod—skin cancer	0.00044	0.00399	CcSEcCtD
Procainamide—BCHE—skin of body—skin cancer	0.000439	0.0106	CbGeAlD
Procainamide—Gastrointestinal pain—Imiquimod—skin cancer	0.000437	0.00396	CcSEcCtD
Procainamide—Agranulocytosis—Fluorouracil—skin cancer	0.000431	0.00391	CcSEcCtD
Procainamide—Ill-defined disorder—Bleomycin—skin cancer	0.000431	0.00391	CcSEcCtD
Procainamide—CHRM2—head—skin cancer	0.000431	0.0104	CbGeAlD
Procainamide—Diarrhoea—Vemurafenib—skin cancer	0.000428	0.00389	CcSEcCtD
Procainamide—Urticaria—Imiquimod—skin cancer	0.000424	0.00385	CcSEcCtD
Procainamide—SLC22A1—head—skin cancer	0.000423	0.0102	CbGeAlD
Procainamide—Abdominal pain—Imiquimod—skin cancer	0.000422	0.00383	CcSEcCtD
Procainamide—Body temperature increased—Imiquimod—skin cancer	0.000422	0.00383	CcSEcCtD
Procainamide—Malaise—Bleomycin—skin cancer	0.000419	0.0038	CcSEcCtD
Procainamide—SCN7A—Developmental Biology—SCN10A—skin cancer	0.000419	0.00676	CbGpPWpGaD
Procainamide—Cardiac disorder—Temozolomide—skin cancer	0.000418	0.00379	CcSEcCtD
Procainamide—Flushing—Temozolomide—skin cancer	0.000418	0.00379	CcSEcCtD
Procainamide—Dizziness—Vemurafenib—skin cancer	0.000414	0.00376	CcSEcCtD
Procainamide—ACHE—lymph node—skin cancer	0.000408	0.00988	CbGeAlD
Procainamide—SLC22A3—head—skin cancer	0.000404	0.00979	CbGeAlD
Procainamide—Chills—Temozolomide—skin cancer	0.000404	0.00367	CcSEcCtD
Procainamide—Ill-defined disorder—Dactinomycin—skin cancer	0.000402	0.00365	CcSEcCtD
Procainamide—BCHE—mammalian vulva—skin cancer	0.0004	0.00969	CbGeAlD
Procainamide—Vomiting—Vemurafenib—skin cancer	0.000398	0.00361	CcSEcCtD
Procainamide—Myalgia—Bleomycin—skin cancer	0.000396	0.00359	CcSEcCtD
Procainamide—Abdominal pain upper—Docetaxel—skin cancer	0.000395	0.00359	CcSEcCtD
Procainamide—Hypersensitivity—Imiquimod—skin cancer	0.000393	0.00357	CcSEcCtD
Procainamide—Discomfort—Bleomycin—skin cancer	0.000391	0.00355	CcSEcCtD
Procainamide—Malaise—Dactinomycin—skin cancer	0.000391	0.00355	CcSEcCtD
Procainamide—SCN10A—lymph node—skin cancer	0.00039	0.00944	CbGeAlD
Procainamide—SCN9A—Axon guidance—SCN10A—skin cancer	0.000387	0.00625	CbGpPWpGaD
Procainamide—Dysgeusia—Temozolomide—skin cancer	0.000384	0.00348	CcSEcCtD
Procainamide—Asthenia—Imiquimod—skin cancer	0.000383	0.00348	CcSEcCtD
Procainamide—Confusional state—Bleomycin—skin cancer	0.000383	0.00347	CcSEcCtD
Procainamide—Pruritus—Imiquimod—skin cancer	0.000378	0.00343	CcSEcCtD
Procainamide—DNMT1—NoRC negatively regulates rRNA expression—ERCC2—skin cancer	0.000376	0.00608	CbGpPWpGaD
Procainamide—SCN11A—Developmental Biology—SCN10A—skin cancer	0.000373	0.00603	CbGpPWpGaD
Procainamide—Nausea—Vemurafenib—skin cancer	0.000372	0.00337	CcSEcCtD
Procainamide—Thrombocytopenia—Bleomycin—skin cancer	0.000371	0.00337	CcSEcCtD
Procainamide—SCN3A—Axon guidance—SCN10A—skin cancer	0.00037	0.00598	CbGpPWpGaD
Procainamide—Myalgia—Dactinomycin—skin cancer	0.000369	0.00335	CcSEcCtD
Procainamide—DNMT1—Negative epigenetic regulation of rRNA expression—ERCC2—skin cancer	0.000368	0.00594	CbGpPWpGaD
Procainamide—SLC22A4—SLC-mediated transmembrane transport—SLC12A2—skin cancer	0.000367	0.00594	CbGpPWpGaD
Procainamide—Diarrhoea—Imiquimod—skin cancer	0.000365	0.00331	CcSEcCtD
Procainamide—Discomfort—Dactinomycin—skin cancer	0.000365	0.00331	CcSEcCtD
Procainamide—Ill-defined disorder—Temozolomide—skin cancer	0.000364	0.0033	CcSEcCtD
Procainamide—Anorexia—Bleomycin—skin cancer	0.000362	0.00328	CcSEcCtD
Procainamide—DNMT1—Retinoblastoma (RB) in Cancer—CDK4—skin cancer	0.000358	0.00579	CbGpPWpGaD
Procainamide—Angioedema—Temozolomide—skin cancer	0.000358	0.00325	CcSEcCtD
Procainamide—SCN4A—Axon guidance—SCN10A—skin cancer	0.000355	0.00574	CbGpPWpGaD
Procainamide—SCN2A—Axon guidance—SCN10A—skin cancer	0.000355	0.00574	CbGpPWpGaD
Procainamide—SCN3A—lymph node—skin cancer	0.000355	0.0086	CbGeAlD
Procainamide—Hypotension—Bleomycin—skin cancer	0.000354	0.00322	CcSEcCtD
Procainamide—Malaise—Temozolomide—skin cancer	0.000354	0.00321	CcSEcCtD
Procainamide—Dizziness—Imiquimod—skin cancer	0.000353	0.0032	CcSEcCtD
Procainamide—SLC22A5—female reproductive system—skin cancer	0.000352	0.00852	CbGeAlD
Procainamide—Neutropenia—Docetaxel—skin cancer	0.00035	0.00317	CcSEcCtD
Procainamide—Thrombocytopenia—Dactinomycin—skin cancer	0.000346	0.00314	CcSEcCtD
Procainamide—Musculoskeletal discomfort—Bleomycin—skin cancer	0.000346	0.00314	CcSEcCtD
Procainamide—BCHE—female reproductive system—skin cancer	0.000343	0.0083	CbGeAlD
Procainamide—SCN1A—Axon guidance—SCN10A—skin cancer	0.000343	0.00554	CbGpPWpGaD
Procainamide—DNMT1—Regulation of retinoblastoma protein—CDKN2A—skin cancer	0.000342	0.00552	CbGpPWpGaD
Procainamide—SCN8A—Developmental Biology—SCN10A—skin cancer	0.000341	0.00551	CbGpPWpGaD
Procainamide—Convulsion—Temozolomide—skin cancer	0.00034	0.00308	CcSEcCtD
Procainamide—Vomiting—Imiquimod—skin cancer	0.00034	0.00308	CcSEcCtD
Procainamide—Anorexia—Dactinomycin—skin cancer	0.000337	0.00306	CcSEcCtD
Procainamide—SCN7A—Axon guidance—RASA1—skin cancer	0.000337	0.00544	CbGpPWpGaD
Procainamide—Arthralgia—Temozolomide—skin cancer	0.000334	0.00303	CcSEcCtD
Procainamide—Myalgia—Temozolomide—skin cancer	0.000334	0.00303	CcSEcCtD
Procainamide—Discomfort—Temozolomide—skin cancer	0.00033	0.00299	CcSEcCtD
Procainamide—Decreased appetite—Bleomycin—skin cancer	0.00033	0.00299	CcSEcCtD
Procainamide—Renal failure—Docetaxel—skin cancer	0.000328	0.00298	CcSEcCtD
Procainamide—DNMT1—Epigenetic regulation of gene expression—ERCC2—skin cancer	0.000326	0.00527	CbGpPWpGaD
Procainamide—Confusional state—Temozolomide—skin cancer	0.000323	0.00293	CcSEcCtD
Procainamide—Musculoskeletal discomfort—Dactinomycin—skin cancer	0.000322	0.00292	CcSEcCtD
Procainamide—Nausea—Imiquimod—skin cancer	0.000317	0.00288	CcSEcCtD
Procainamide—Thrombocytopenia—Temozolomide—skin cancer	0.000313	0.00284	CcSEcCtD
Procainamide—Convulsion—Fluorouracil—skin cancer	0.000313	0.00284	CcSEcCtD
Procainamide—Feeling abnormal—Bleomycin—skin cancer	0.000313	0.00284	CcSEcCtD
Procainamide—Agranulocytosis—Docetaxel—skin cancer	0.000311	0.00282	CcSEcCtD
Procainamide—SLC22A4—lymph node—skin cancer	0.000311	0.00753	CbGeAlD
Procainamide—Myalgia—Fluorouracil—skin cancer	0.000308	0.00279	CcSEcCtD
Procainamide—Decreased appetite—Dactinomycin—skin cancer	0.000308	0.00279	CcSEcCtD
Procainamide—Anorexia—Temozolomide—skin cancer	0.000305	0.00277	CcSEcCtD
Procainamide—Discomfort—Fluorouracil—skin cancer	0.000304	0.00276	CcSEcCtD
Procainamide—Urticaria—Bleomycin—skin cancer	0.000301	0.00273	CcSEcCtD
Procainamide—SCN11A—Axon guidance—RASA1—skin cancer	0.0003	0.00485	CbGpPWpGaD
Procainamide—Body temperature increased—Bleomycin—skin cancer	0.0003	0.00272	CcSEcCtD
Procainamide—Confusional state—Fluorouracil—skin cancer	0.000297	0.0027	CcSEcCtD
Procainamide—Feeling abnormal—Dactinomycin—skin cancer	0.000292	0.00264	CcSEcCtD
Procainamide—Musculoskeletal discomfort—Temozolomide—skin cancer	0.000292	0.00264	CcSEcCtD
Procainamide—Gastrointestinal pain—Dactinomycin—skin cancer	0.000289	0.00262	CcSEcCtD
Procainamide—Thrombocytopenia—Fluorouracil—skin cancer	0.000289	0.00262	CcSEcCtD
Procainamide—BCHE—head—skin cancer	0.000286	0.00693	CbGeAlD
Procainamide—SLC22A3—lymph node—skin cancer	0.000283	0.00686	CbGeAlD
Procainamide—Anorexia—Fluorouracil—skin cancer	0.000281	0.00255	CcSEcCtD
Procainamide—Abdominal pain—Dactinomycin—skin cancer	0.00028	0.00254	CcSEcCtD
Procainamide—Body temperature increased—Dactinomycin—skin cancer	0.00028	0.00254	CcSEcCtD
Procainamide—Hypersensitivity—Bleomycin—skin cancer	0.00028	0.00254	CcSEcCtD
Procainamide—Decreased appetite—Temozolomide—skin cancer	0.000278	0.00252	CcSEcCtD
Procainamide—Cardiac disorder—Docetaxel—skin cancer	0.000278	0.00252	CcSEcCtD
Procainamide—Flushing—Docetaxel—skin cancer	0.000278	0.00252	CcSEcCtD
Procainamide—SLC22A3—SLC-mediated transmembrane transport—SLC12A2—skin cancer	0.000277	0.00448	CbGpPWpGaD
Procainamide—SLC22A5—SLC-mediated transmembrane transport—SLC12A2—skin cancer	0.000276	0.00446	CbGpPWpGaD
Procainamide—SCN9A—Developmental Biology—SCN10A—skin cancer	0.000276	0.00446	CbGpPWpGaD
Procainamide—Hypotension—Fluorouracil—skin cancer	0.000276	0.0025	CcSEcCtD
Procainamide—SCN8A—Axon guidance—RASA1—skin cancer	0.000275	0.00444	CbGpPWpGaD
Procainamide—Asthenia—Bleomycin—skin cancer	0.000272	0.00247	CcSEcCtD
Procainamide—Chills—Docetaxel—skin cancer	0.000269	0.00244	CcSEcCtD
Procainamide—Musculoskeletal discomfort—Fluorouracil—skin cancer	0.000269	0.00244	CcSEcCtD
Procainamide—Pruritus—Bleomycin—skin cancer	0.000268	0.00243	CcSEcCtD
Procainamide—SCN3A—Developmental Biology—SCN10A—skin cancer	0.000264	0.00426	CbGpPWpGaD
Procainamide—Feeling abnormal—Temozolomide—skin cancer	0.000264	0.00239	CcSEcCtD
Procainamide—Gastrointestinal pain—Temozolomide—skin cancer	0.000262	0.00237	CcSEcCtD
Procainamide—Hypersensitivity—Dactinomycin—skin cancer	0.000261	0.00236	CcSEcCtD
Procainamide—Decreased appetite—Fluorouracil—skin cancer	0.000256	0.00232	CcSEcCtD
Procainamide—Dysgeusia—Docetaxel—skin cancer	0.000255	0.00232	CcSEcCtD
Procainamide—Urticaria—Temozolomide—skin cancer	0.000254	0.00231	CcSEcCtD
Procainamide—Asthenia—Dactinomycin—skin cancer	0.000254	0.0023	CcSEcCtD
Procainamide—SCN4A—Developmental Biology—SCN10A—skin cancer	0.000254	0.0041	CbGpPWpGaD
Procainamide—SCN2A—Developmental Biology—SCN10A—skin cancer	0.000254	0.0041	CbGpPWpGaD
Procainamide—Abdominal pain—Temozolomide—skin cancer	0.000253	0.00229	CcSEcCtD
Procainamide—Body temperature increased—Temozolomide—skin cancer	0.000253	0.00229	CcSEcCtD
Procainamide—SCN1A—Developmental Biology—SCN10A—skin cancer	0.000245	0.00395	CbGpPWpGaD
Procainamide—Feeling abnormal—Fluorouracil—skin cancer	0.000243	0.0022	CcSEcCtD
Procainamide—Diarrhoea—Dactinomycin—skin cancer	0.000242	0.0022	CcSEcCtD
Procainamide—Vomiting—Bleomycin—skin cancer	0.000241	0.00219	CcSEcCtD
Procainamide—SCN5A—Axon guidance—SCN10A—skin cancer	0.000241	0.00389	CbGpPWpGaD
Procainamide—SCN7A—Developmental Biology—RASA1—skin cancer	0.00024	0.00388	CbGpPWpGaD
Procainamide—Hypersensitivity—Temozolomide—skin cancer	0.000236	0.00214	CcSEcCtD
Procainamide—Urticaria—Fluorouracil—skin cancer	0.000234	0.00212	CcSEcCtD
Procainamide—Body temperature increased—Fluorouracil—skin cancer	0.000233	0.00211	CcSEcCtD
Procainamide—Asthenia—Temozolomide—skin cancer	0.00023	0.00208	CcSEcCtD
Procainamide—CYP2D6—female reproductive system—skin cancer	0.000227	0.0055	CbGeAlD
Procainamide—Pruritus—Temozolomide—skin cancer	0.000226	0.00205	CcSEcCtD
Procainamide—Convulsion—Docetaxel—skin cancer	0.000226	0.00205	CcSEcCtD
Procainamide—Nausea—Bleomycin—skin cancer	0.000225	0.00204	CcSEcCtD
Procainamide—Vomiting—Dactinomycin—skin cancer	0.000225	0.00204	CcSEcCtD
Procainamide—SCN9A—Axon guidance—RASA1—skin cancer	0.000222	0.00359	CbGpPWpGaD
Procainamide—Myalgia—Docetaxel—skin cancer	0.000222	0.00201	CcSEcCtD
Procainamide—Arthralgia—Docetaxel—skin cancer	0.000222	0.00201	CcSEcCtD
Procainamide—Diarrhoea—Temozolomide—skin cancer	0.000219	0.00199	CcSEcCtD
Procainamide—Hypersensitivity—Fluorouracil—skin cancer	0.000217	0.00197	CcSEcCtD
Procainamide—Confusional state—Docetaxel—skin cancer	0.000215	0.00195	CcSEcCtD
Procainamide—SCN11A—Developmental Biology—RASA1—skin cancer	0.000214	0.00346	CbGpPWpGaD
Procainamide—SCN3A—Axon guidance—RASA1—skin cancer	0.000212	0.00343	CbGpPWpGaD
Procainamide—Dizziness—Temozolomide—skin cancer	0.000212	0.00192	CcSEcCtD
Procainamide—Nausea—Dactinomycin—skin cancer	0.00021	0.00191	CcSEcCtD
Procainamide—Shock—Docetaxel—skin cancer	0.000209	0.0019	CcSEcCtD
Procainamide—Pruritus—Fluorouracil—skin cancer	0.000209	0.00189	CcSEcCtD
Procainamide—Thrombocytopenia—Docetaxel—skin cancer	0.000208	0.00189	CcSEcCtD
Procainamide—SLC22A5—lymph node—skin cancer	0.000206	0.00499	CbGeAlD
Procainamide—SCN4A—Axon guidance—RASA1—skin cancer	0.000204	0.0033	CbGpPWpGaD
Procainamide—SCN2A—Axon guidance—RASA1—skin cancer	0.000204	0.0033	CbGpPWpGaD
Procainamide—Vomiting—Temozolomide—skin cancer	0.000203	0.00185	CcSEcCtD
Procainamide—Anorexia—Docetaxel—skin cancer	0.000203	0.00184	CcSEcCtD
Procainamide—Diarrhoea—Fluorouracil—skin cancer	0.000202	0.00183	CcSEcCtD
Procainamide—ACHE—ATF-2 transcription factor network—CDK4—skin cancer	0.000201	0.00325	CbGpPWpGaD
Procainamide—BCHE—lymph node—skin cancer	0.000201	0.00486	CbGeAlD
Procainamide—Hypotension—Docetaxel—skin cancer	0.000199	0.0018	CcSEcCtD
Procainamide—SCN10A—Axon guidance—RASA1—skin cancer	0.000197	0.00318	CbGpPWpGaD
Procainamide—SCN1A—Axon guidance—RASA1—skin cancer	0.000197	0.00318	CbGpPWpGaD
Procainamide—SCN8A—Developmental Biology—RASA1—skin cancer	0.000196	0.00317	CbGpPWpGaD
Procainamide—Dizziness—Fluorouracil—skin cancer	0.000195	0.00177	CcSEcCtD
Procainamide—Musculoskeletal discomfort—Docetaxel—skin cancer	0.000194	0.00176	CcSEcCtD
Procainamide—Nausea—Temozolomide—skin cancer	0.00019	0.00172	CcSEcCtD
Procainamide—CYP2D6—head—skin cancer	0.00019	0.00459	CbGeAlD
Procainamide—CHRM2—GPCRs, Other—SMO—skin cancer	0.000188	0.00304	CbGpPWpGaD
Procainamide—Vomiting—Fluorouracil—skin cancer	0.000187	0.0017	CcSEcCtD
Procainamide—SLC22A4—Transmembrane transport of small molecules—SLC12A2—skin cancer	0.000187	0.00302	CbGpPWpGaD
Procainamide—Decreased appetite—Docetaxel—skin cancer	0.000185	0.00168	CcSEcCtD
Procainamide—Feeling abnormal—Docetaxel—skin cancer	0.000175	0.00159	CcSEcCtD
Procainamide—Nausea—Fluorouracil—skin cancer	0.000175	0.00159	CcSEcCtD
Procainamide—Gastrointestinal pain—Docetaxel—skin cancer	0.000174	0.00158	CcSEcCtD
Procainamide—SLC22A2—SLC-mediated transmembrane transport—SLC12A2—skin cancer	0.000174	0.00281	CbGpPWpGaD
Procainamide—SCN5A—Developmental Biology—SCN10A—skin cancer	0.000172	0.00278	CbGpPWpGaD
Procainamide—Body temperature increased—Docetaxel—skin cancer	0.000168	0.00153	CcSEcCtD
Procainamide—Abdominal pain—Docetaxel—skin cancer	0.000168	0.00153	CcSEcCtD
Procainamide—SLC22A1—SLC-mediated transmembrane transport—SLC12A2—skin cancer	0.000162	0.00262	CbGpPWpGaD
Procainamide—ACHE—Integrated Pancreatic Cancer Pathway—SHH—skin cancer	0.000161	0.00261	CbGpPWpGaD
Procainamide—SCN9A—Developmental Biology—RASA1—skin cancer	0.000158	0.00256	CbGpPWpGaD
Procainamide—Hypersensitivity—Docetaxel—skin cancer	0.000157	0.00142	CcSEcCtD
Procainamide—ACHE—Integrated Pancreatic Cancer Pathway—SMO—skin cancer	0.000153	0.00247	CbGpPWpGaD
Procainamide—Asthenia—Docetaxel—skin cancer	0.000153	0.00138	CcSEcCtD
Procainamide—DNMT1—Retinoblastoma (RB) in Cancer—TP53—skin cancer	0.000152	0.00246	CbGpPWpGaD
Procainamide—SCN3A—Developmental Biology—RASA1—skin cancer	0.000152	0.00245	CbGpPWpGaD
Procainamide—Pruritus—Docetaxel—skin cancer	0.000151	0.00137	CcSEcCtD
Procainamide—SCN2A—Developmental Biology—RASA1—skin cancer	0.000146	0.00235	CbGpPWpGaD
Procainamide—SCN4A—Developmental Biology—RASA1—skin cancer	0.000146	0.00235	CbGpPWpGaD
Procainamide—Diarrhoea—Docetaxel—skin cancer	0.000146	0.00132	CcSEcCtD
Procainamide—SLC22A3—Transmembrane transport of small molecules—SLC12A2—skin cancer	0.000141	0.00228	CbGpPWpGaD
Procainamide—Dizziness—Docetaxel—skin cancer	0.000141	0.00128	CcSEcCtD
Procainamide—SCN1A—Developmental Biology—RASA1—skin cancer	0.00014	0.00227	CbGpPWpGaD
Procainamide—SCN10A—Developmental Biology—RASA1—skin cancer	0.00014	0.00227	CbGpPWpGaD
Procainamide—SLC22A5—Transmembrane transport of small molecules—SLC12A2—skin cancer	0.00014	0.00227	CbGpPWpGaD
Procainamide—SCN5A—Axon guidance—RASA1—skin cancer	0.000138	0.00224	CbGpPWpGaD
Procainamide—Vomiting—Docetaxel—skin cancer	0.000135	0.00123	CcSEcCtD
Procainamide—ACHE—Metabolism of proteins—EXOC2—skin cancer	0.000133	0.00215	CbGpPWpGaD
Procainamide—Nausea—Docetaxel—skin cancer	0.000126	0.00115	CcSEcCtD
Procainamide—ACHE—Metabolism of lipids and lipoproteins—PLIN2—skin cancer	0.000123	0.00199	CbGpPWpGaD
Procainamide—CHRM2—GPCRs, Class A Rhodopsin-like—MC1R—skin cancer	0.000121	0.00195	CbGpPWpGaD
Procainamide—BCHE—Metabolism of proteins—EXOC2—skin cancer	0.000119	0.00192	CbGpPWpGaD
Procainamide—SCN7A—Developmental Biology—CDK4—skin cancer	0.000118	0.0019	CbGpPWpGaD
Procainamide—BCHE—Metabolism of lipids and lipoproteins—PLIN2—skin cancer	0.00011	0.00177	CbGpPWpGaD
Procainamide—CHRM2—GPCR ligand binding—PTCH2—skin cancer	0.000109	0.00176	CbGpPWpGaD
Procainamide—SCN11A—Developmental Biology—CDK4—skin cancer	0.000105	0.0017	CbGpPWpGaD
Procainamide—CHRM2—Class A/1 (Rhodopsin-like receptors)—MC1R—skin cancer	0.000104	0.00167	CbGpPWpGaD
Procainamide—SCN5A—Developmental Biology—RASA1—skin cancer	9.87e-05	0.0016	CbGpPWpGaD
Procainamide—SCN8A—Developmental Biology—CDK4—skin cancer	9.61e-05	0.00155	CbGpPWpGaD
Procainamide—SCN7A—Axon guidance—NRAS—skin cancer	9.19e-05	0.00148	CbGpPWpGaD
Procainamide—SLC22A2—Transmembrane transport of small molecules—SLC12A2—skin cancer	8.83e-05	0.00143	CbGpPWpGaD
Procainamide—SLC22A1—Transmembrane transport of small molecules—SLC12A2—skin cancer	8.23e-05	0.00133	CbGpPWpGaD
Procainamide—SCN11A—Axon guidance—NRAS—skin cancer	8.19e-05	0.00132	CbGpPWpGaD
Procainamide—CHRM2—GPCRs, Class A Rhodopsin-like—PTGER4—skin cancer	7.95e-05	0.00128	CbGpPWpGaD
Procainamide—SCN7A—Axon guidance—KRAS—skin cancer	7.91e-05	0.00128	CbGpPWpGaD
Procainamide—CHRM2—GPCR ligand binding—MC1R—skin cancer	7.89e-05	0.00127	CbGpPWpGaD
Procainamide—ACHE—Integrated Pancreatic Cancer Pathway—CDK4—skin cancer	7.86e-05	0.00127	CbGpPWpGaD
Procainamide—ACHE—ATF-2 transcription factor network—IL6—skin cancer	7.84e-05	0.00127	CbGpPWpGaD
Procainamide—SCN9A—Developmental Biology—CDK4—skin cancer	7.77e-05	0.00126	CbGpPWpGaD
Procainamide—SCN8A—Axon guidance—NRAS—skin cancer	7.49e-05	0.00121	CbGpPWpGaD
Procainamide—SCN3A—Developmental Biology—CDK4—skin cancer	7.43e-05	0.0012	CbGpPWpGaD
Procainamide—SCN4A—Developmental Biology—CDK4—skin cancer	7.14e-05	0.00115	CbGpPWpGaD
Procainamide—SCN2A—Developmental Biology—CDK4—skin cancer	7.14e-05	0.00115	CbGpPWpGaD
Procainamide—SCN11A—Axon guidance—KRAS—skin cancer	7.05e-05	0.00114	CbGpPWpGaD
Procainamide—SLC22A3—Metabolism—PLIN2—skin cancer	6.96e-05	0.00112	CbGpPWpGaD
Procainamide—SCN10A—Developmental Biology—CDK4—skin cancer	6.89e-05	0.00111	CbGpPWpGaD
Procainamide—SCN1A—Developmental Biology—CDK4—skin cancer	6.89e-05	0.00111	CbGpPWpGaD
Procainamide—CHRM2—Class A/1 (Rhodopsin-like receptors)—PTGER4—skin cancer	6.81e-05	0.0011	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—RHOU—skin cancer	6.77e-05	0.00109	CbGpPWpGaD
Procainamide—SCN7A—Axon guidance—HRAS—skin cancer	6.72e-05	0.00109	CbGpPWpGaD
Procainamide—ACHE—Transmission across Chemical Synapses—BRAF—skin cancer	6.71e-05	0.00108	CbGpPWpGaD
Procainamide—SCN7A—Developmental Biology—NRAS—skin cancer	6.56e-05	0.00106	CbGpPWpGaD
Procainamide—SCN8A—Axon guidance—KRAS—skin cancer	6.45e-05	0.00104	CbGpPWpGaD
Procainamide—SCN7A—Axon guidance—IL6—skin cancer	6.43e-05	0.00104	CbGpPWpGaD
Procainamide—SCN9A—Axon guidance—NRAS—skin cancer	6.06e-05	0.000979	CbGpPWpGaD
Procainamide—SCN11A—Axon guidance—HRAS—skin cancer	5.99e-05	0.000968	CbGpPWpGaD
Procainamide—BCHE—Transmission across Chemical Synapses—BRAF—skin cancer	5.98e-05	0.000967	CbGpPWpGaD
Procainamide—SCN11A—Developmental Biology—NRAS—skin cancer	5.84e-05	0.000944	CbGpPWpGaD
Procainamide—SCN3A—Axon guidance—NRAS—skin cancer	5.79e-05	0.000936	CbGpPWpGaD
Procainamide—CHRM2—Regulation of Actin Cytoskeleton—BRAF—skin cancer	5.76e-05	0.000931	CbGpPWpGaD
Procainamide—SCN11A—Axon guidance—IL6—skin cancer	5.73e-05	0.000926	CbGpPWpGaD
Procainamide—SCN7A—Developmental Biology—KRAS—skin cancer	5.64e-05	0.000912	CbGpPWpGaD
Procainamide—CHRM2—GPCR ligand binding—SHH—skin cancer	5.62e-05	0.000908	CbGpPWpGaD
Procainamide—ACHE—Integrated Pancreatic Cancer Pathway—PTGS2—skin cancer	5.62e-05	0.000908	CbGpPWpGaD
Procainamide—SLC22A3—Metabolism—CSPG4—skin cancer	5.61e-05	0.000906	CbGpPWpGaD
Procainamide—CHRM2—Signaling by GPCR—PTCH2—skin cancer	5.6e-05	0.000905	CbGpPWpGaD
Procainamide—SCN2A—Axon guidance—NRAS—skin cancer	5.57e-05	0.000899	CbGpPWpGaD
Procainamide—SCN4A—Axon guidance—NRAS—skin cancer	5.57e-05	0.000899	CbGpPWpGaD
Procainamide—SCN8A—Axon guidance—HRAS—skin cancer	5.48e-05	0.000885	CbGpPWpGaD
Procainamide—ACHE—Metabolism—PLIN2—skin cancer	5.48e-05	0.000885	CbGpPWpGaD
Procainamide—DNMT1—Gene Expression—ERCC2—skin cancer	5.45e-05	0.00088	CbGpPWpGaD
Procainamide—SCN10A—Axon guidance—NRAS—skin cancer	5.37e-05	0.000867	CbGpPWpGaD
Procainamide—SCN1A—Axon guidance—NRAS—skin cancer	5.37e-05	0.000867	CbGpPWpGaD
Procainamide—SCN8A—Developmental Biology—NRAS—skin cancer	5.34e-05	0.000864	CbGpPWpGaD
Procainamide—SLC22A2—Transmission across Chemical Synapses—BRAF—skin cancer	5.34e-05	0.000863	CbGpPWpGaD
Procainamide—CHRM2—GPCR ligand binding—PTCH1—skin cancer	5.33e-05	0.000861	CbGpPWpGaD
Procainamide—CHRM2—GPCR ligand binding—SMO—skin cancer	5.33e-05	0.000861	CbGpPWpGaD
Procainamide—SCN8A—Axon guidance—IL6—skin cancer	5.24e-05	0.000847	CbGpPWpGaD
Procainamide—SCN9A—Axon guidance—KRAS—skin cancer	5.21e-05	0.000842	CbGpPWpGaD
Procainamide—CHRM2—GPCR ligand binding—PTGER4—skin cancer	5.19e-05	0.000838	CbGpPWpGaD
Procainamide—ACHE—Neuronal System—BRAF—skin cancer	5.14e-05	0.00083	CbGpPWpGaD
Procainamide—SCN11A—Developmental Biology—KRAS—skin cancer	5.03e-05	0.000813	CbGpPWpGaD
Procainamide—SCN3A—Axon guidance—KRAS—skin cancer	4.99e-05	0.000806	CbGpPWpGaD
Procainamide—SLC22A1—Transmission across Chemical Synapses—BRAF—skin cancer	4.98e-05	0.000805	CbGpPWpGaD
Procainamide—BCHE—Metabolism—PLIN2—skin cancer	4.88e-05	0.000789	CbGpPWpGaD
Procainamide—SCN5A—Developmental Biology—CDK4—skin cancer	4.84e-05	0.000782	CbGpPWpGaD
Procainamide—SCN7A—Developmental Biology—HRAS—skin cancer	4.8e-05	0.000775	CbGpPWpGaD
Procainamide—SCN2A—Axon guidance—KRAS—skin cancer	4.79e-05	0.000774	CbGpPWpGaD
Procainamide—SCN4A—Axon guidance—KRAS—skin cancer	4.79e-05	0.000774	CbGpPWpGaD
Procainamide—SCN5A—SIDS Susceptibility Pathways—IL6—skin cancer	4.74e-05	0.000766	CbGpPWpGaD
Procainamide—SCN10A—Axon guidance—KRAS—skin cancer	4.62e-05	0.000746	CbGpPWpGaD
Procainamide—SCN1A—Axon guidance—KRAS—skin cancer	4.62e-05	0.000746	CbGpPWpGaD
Procainamide—SCN8A—Developmental Biology—KRAS—skin cancer	4.6e-05	0.000743	CbGpPWpGaD
Procainamide—SCN7A—Developmental Biology—IL6—skin cancer	4.59e-05	0.000742	CbGpPWpGaD
Procainamide—BCHE—Neuronal System—BRAF—skin cancer	4.58e-05	0.000741	CbGpPWpGaD
Procainamide—CHRM2—GPCR downstream signaling—MC1R—skin cancer	4.46e-05	0.00072	CbGpPWpGaD
Procainamide—SCN9A—Axon guidance—HRAS—skin cancer	4.43e-05	0.000716	CbGpPWpGaD
Procainamide—ACHE—Metabolism—CSPG4—skin cancer	4.41e-05	0.000713	CbGpPWpGaD
Procainamide—SLC22A2—Metabolism—PLIN2—skin cancer	4.36e-05	0.000705	CbGpPWpGaD
Procainamide—SCN9A—Developmental Biology—NRAS—skin cancer	4.32e-05	0.000698	CbGpPWpGaD
Procainamide—SCN11A—Developmental Biology—HRAS—skin cancer	4.27e-05	0.000691	CbGpPWpGaD
Procainamide—SCN9A—Axon guidance—IL6—skin cancer	4.24e-05	0.000685	CbGpPWpGaD
Procainamide—SCN3A—Axon guidance—HRAS—skin cancer	4.24e-05	0.000685	CbGpPWpGaD
Procainamide—SCN3A—Developmental Biology—NRAS—skin cancer	4.13e-05	0.000668	CbGpPWpGaD
Procainamide—SLC22A2—Neuronal System—BRAF—skin cancer	4.09e-05	0.000661	CbGpPWpGaD
Procainamide—SCN11A—Developmental Biology—IL6—skin cancer	4.09e-05	0.000661	CbGpPWpGaD
Procainamide—SCN2A—Axon guidance—HRAS—skin cancer	4.07e-05	0.000658	CbGpPWpGaD
Procainamide—SCN4A—Axon guidance—HRAS—skin cancer	4.07e-05	0.000658	CbGpPWpGaD
Procainamide—SLC22A1—Metabolism—PLIN2—skin cancer	4.07e-05	0.000657	CbGpPWpGaD
Procainamide—SCN3A—Axon guidance—IL6—skin cancer	4.06e-05	0.000655	CbGpPWpGaD
Procainamide—CHRM2—Signaling by GPCR—MC1R—skin cancer	4.05e-05	0.000654	CbGpPWpGaD
Procainamide—SCN2A—Developmental Biology—NRAS—skin cancer	3.97e-05	0.000642	CbGpPWpGaD
Procainamide—SCN4A—Developmental Biology—NRAS—skin cancer	3.97e-05	0.000642	CbGpPWpGaD
Procainamide—BCHE—Metabolism—CSPG4—skin cancer	3.94e-05	0.000636	CbGpPWpGaD
Procainamide—SCN10A—Axon guidance—HRAS—skin cancer	3.93e-05	0.000634	CbGpPWpGaD
Procainamide—SCN1A—Axon guidance—HRAS—skin cancer	3.93e-05	0.000634	CbGpPWpGaD
Procainamide—SCN8A—Developmental Biology—HRAS—skin cancer	3.91e-05	0.000632	CbGpPWpGaD
Procainamide—SCN4A—Axon guidance—IL6—skin cancer	3.9e-05	0.00063	CbGpPWpGaD
Procainamide—SCN2A—Axon guidance—IL6—skin cancer	3.9e-05	0.00063	CbGpPWpGaD
Procainamide—SCN10A—Developmental Biology—NRAS—skin cancer	3.83e-05	0.000619	CbGpPWpGaD
Procainamide—SCN1A—Developmental Biology—NRAS—skin cancer	3.83e-05	0.000619	CbGpPWpGaD
Procainamide—SLC22A1—Neuronal System—BRAF—skin cancer	3.82e-05	0.000617	CbGpPWpGaD
Procainamide—SLC22A3—Metabolism—ENO2—skin cancer	3.81e-05	0.000616	CbGpPWpGaD
Procainamide—SCN5A—Axon guidance—NRAS—skin cancer	3.77e-05	0.00061	CbGpPWpGaD
Procainamide—ACHE—Integrated Pancreatic Cancer Pathway—KRAS—skin cancer	3.76e-05	0.000608	CbGpPWpGaD
Procainamide—SCN10A—Axon guidance—IL6—skin cancer	3.76e-05	0.000607	CbGpPWpGaD
Procainamide—SCN1A—Axon guidance—IL6—skin cancer	3.76e-05	0.000607	CbGpPWpGaD
Procainamide—SCN8A—Developmental Biology—IL6—skin cancer	3.74e-05	0.000605	CbGpPWpGaD
Procainamide—SCN9A—Developmental Biology—KRAS—skin cancer	3.72e-05	0.000601	CbGpPWpGaD
Procainamide—CHRM2—Regulation of Actin Cytoskeleton—NRAS—skin cancer	3.62e-05	0.000585	CbGpPWpGaD
Procainamide—SCN3A—Developmental Biology—KRAS—skin cancer	3.56e-05	0.000575	CbGpPWpGaD
Procainamide—SLC22A2—Metabolism—CSPG4—skin cancer	3.52e-05	0.000568	CbGpPWpGaD
Procainamide—SCN4A—Developmental Biology—KRAS—skin cancer	3.42e-05	0.000552	CbGpPWpGaD
Procainamide—SCN2A—Developmental Biology—KRAS—skin cancer	3.42e-05	0.000552	CbGpPWpGaD
Procainamide—ACHE—Integrated Pancreatic Cancer Pathway—TP53—skin cancer	3.34e-05	0.00054	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—PTCH2—skin cancer	3.31e-05	0.000535	CbGpPWpGaD
Procainamide—SCN10A—Developmental Biology—KRAS—skin cancer	3.3e-05	0.000533	CbGpPWpGaD
Procainamide—SCN1A—Developmental Biology—KRAS—skin cancer	3.3e-05	0.000533	CbGpPWpGaD
Procainamide—SLC22A1—Metabolism—CSPG4—skin cancer	3.28e-05	0.00053	CbGpPWpGaD
Procainamide—SCN5A—Axon guidance—KRAS—skin cancer	3.25e-05	0.000525	CbGpPWpGaD
Procainamide—SCN9A—Developmental Biology—HRAS—skin cancer	3.16e-05	0.000511	CbGpPWpGaD
Procainamide—CHRM2—Regulation of Actin Cytoskeleton—KRAS—skin cancer	3.12e-05	0.000504	CbGpPWpGaD
Procainamide—ACHE—Transmission across Chemical Synapses—HRAS—skin cancer	3.08e-05	0.000498	CbGpPWpGaD
Procainamide—SCN9A—Developmental Biology—IL6—skin cancer	3.03e-05	0.000489	CbGpPWpGaD
Procainamide—SCN3A—Developmental Biology—HRAS—skin cancer	3.02e-05	0.000489	CbGpPWpGaD
Procainamide—ACHE—Metabolism—ENO2—skin cancer	3e-05	0.000485	CbGpPWpGaD
Procainamide—CHRM2—GPCR downstream signaling—PTGER4—skin cancer	2.93e-05	0.000474	CbGpPWpGaD
Procainamide—SCN2A—Developmental Biology—HRAS—skin cancer	2.91e-05	0.00047	CbGpPWpGaD
Procainamide—SCN4A—Developmental Biology—HRAS—skin cancer	2.91e-05	0.00047	CbGpPWpGaD
Procainamide—SCN3A—Developmental Biology—IL6—skin cancer	2.89e-05	0.000468	CbGpPWpGaD
Procainamide—CHRM2—Signaling by GPCR—SHH—skin cancer	2.88e-05	0.000466	CbGpPWpGaD
Procainamide—SCN10A—Developmental Biology—HRAS—skin cancer	2.8e-05	0.000453	CbGpPWpGaD
Procainamide—SCN1A—Developmental Biology—HRAS—skin cancer	2.8e-05	0.000453	CbGpPWpGaD
Procainamide—SCN2A—Developmental Biology—IL6—skin cancer	2.78e-05	0.000449	CbGpPWpGaD
Procainamide—SCN4A—Developmental Biology—IL6—skin cancer	2.78e-05	0.000449	CbGpPWpGaD
Procainamide—SCN5A—Axon guidance—HRAS—skin cancer	2.76e-05	0.000446	CbGpPWpGaD
Procainamide—BCHE—Transmission across Chemical Synapses—HRAS—skin cancer	2.75e-05	0.000444	CbGpPWpGaD
Procainamide—CHRM2—Signaling by GPCR—SMO—skin cancer	2.73e-05	0.000442	CbGpPWpGaD
Procainamide—CHRM2—Signaling by GPCR—PTCH1—skin cancer	2.73e-05	0.000442	CbGpPWpGaD
Procainamide—SCN5A—Developmental Biology—NRAS—skin cancer	2.69e-05	0.000435	CbGpPWpGaD
Procainamide—SCN10A—Developmental Biology—IL6—skin cancer	2.68e-05	0.000433	CbGpPWpGaD
Procainamide—SCN1A—Developmental Biology—IL6—skin cancer	2.68e-05	0.000433	CbGpPWpGaD
Procainamide—BCHE—Metabolism—ENO2—skin cancer	2.68e-05	0.000433	CbGpPWpGaD
Procainamide—CHRM2—Signaling by GPCR—PTGER4—skin cancer	2.66e-05	0.00043	CbGpPWpGaD
Procainamide—SCN5A—Axon guidance—IL6—skin cancer	2.64e-05	0.000427	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—GLI2—skin cancer	2.51e-05	0.000405	CbGpPWpGaD
Procainamide—SLC22A2—Transmission across Chemical Synapses—HRAS—skin cancer	2.46e-05	0.000397	CbGpPWpGaD
Procainamide—CHRM2—SIDS Susceptibility Pathways—IL6—skin cancer	2.45e-05	0.000395	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—MC1R—skin cancer	2.39e-05	0.000386	CbGpPWpGaD
Procainamide—SLC22A2—Metabolism—ENO2—skin cancer	2.39e-05	0.000386	CbGpPWpGaD
Procainamide—ACHE—Neuronal System—HRAS—skin cancer	2.36e-05	0.000382	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—GLI1—skin cancer	2.36e-05	0.000381	CbGpPWpGaD
Procainamide—ACHE—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	2.35e-05	0.000379	CbGpPWpGaD
Procainamide—SCN5A—Developmental Biology—KRAS—skin cancer	2.32e-05	0.000374	CbGpPWpGaD
Procainamide—SLC22A1—Transmission across Chemical Synapses—HRAS—skin cancer	2.29e-05	0.00037	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—PLIN2—skin cancer	2.25e-05	0.000363	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—SUFU—skin cancer	2.23e-05	0.000361	CbGpPWpGaD
Procainamide—SLC22A1—Metabolism—ENO2—skin cancer	2.23e-05	0.00036	CbGpPWpGaD
Procainamide—SLC22A3—Metabolism—ERCC2—skin cancer	2.21e-05	0.000358	CbGpPWpGaD
Procainamide—BCHE—Neuronal System—HRAS—skin cancer	2.11e-05	0.00034	CbGpPWpGaD
Procainamide—BCHE—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	2.09e-05	0.000338	CbGpPWpGaD
Procainamide—SCN5A—Developmental Biology—HRAS—skin cancer	1.97e-05	0.000318	CbGpPWpGaD
Procainamide—SCN5A—Developmental Biology—IL6—skin cancer	1.89e-05	0.000305	CbGpPWpGaD
Procainamide—SLC22A2—Neuronal System—HRAS—skin cancer	1.88e-05	0.000304	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—CSPG4—skin cancer	1.81e-05	0.000293	CbGpPWpGaD
Procainamide—SLC22A1—Neuronal System—HRAS—skin cancer	1.75e-05	0.000283	CbGpPWpGaD
Procainamide—ACHE—Metabolism—ERCC2—skin cancer	1.74e-05	0.000282	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—SHH—skin cancer	1.7e-05	0.000275	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—RASA1—skin cancer	1.69e-05	0.000274	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—PTCH1—skin cancer	1.62e-05	0.000261	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—SMO—skin cancer	1.62e-05	0.000261	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—PTGER4—skin cancer	1.57e-05	0.000254	CbGpPWpGaD
Procainamide—BCHE—Metabolism—ERCC2—skin cancer	1.55e-05	0.000251	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—FOXO4—skin cancer	1.39e-05	0.000225	CbGpPWpGaD
Procainamide—SLC22A2—Metabolism—ERCC2—skin cancer	1.39e-05	0.000224	CbGpPWpGaD
Procainamide—SLC22A3—Metabolism—PTGS2—skin cancer	1.33e-05	0.000215	CbGpPWpGaD
Procainamide—SLC22A1—Metabolism—ERCC2—skin cancer	1.29e-05	0.000209	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—ENO2—skin cancer	1.23e-05	0.000199	CbGpPWpGaD
Procainamide—ACHE—Metabolism—PTGS2—skin cancer	1.04e-05	0.000169	CbGpPWpGaD
Procainamide—BCHE—Metabolism—PTGS2—skin cancer	9.32e-06	0.000151	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—TERT—skin cancer	9.28e-06	0.00015	CbGpPWpGaD
Procainamide—SLC22A2—Metabolism—PTGS2—skin cancer	8.33e-06	0.000135	CbGpPWpGaD
Procainamide—CHRM2—Signaling by GPCR—NRAS—skin cancer	7.82e-06	0.000126	CbGpPWpGaD
Procainamide—SLC22A1—Metabolism—PTGS2—skin cancer	7.76e-06	0.000125	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—BRAF—skin cancer	7.35e-06	0.000119	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—ERCC2—skin cancer	7.15e-06	0.000116	CbGpPWpGaD
Procainamide—CHRM2—Signaling by GPCR—KRAS—skin cancer	6.73e-06	0.000109	CbGpPWpGaD
Procainamide—CHRM2—Signaling by GPCR—HRAS—skin cancer	5.72e-06	9.24e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling by GPCR—IL6—skin cancer	5.47e-06	8.85e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—NRAS—skin cancer	4.62e-06	7.46e-05	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—PTGS2—skin cancer	4.29e-06	6.93e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—KRAS—skin cancer	3.97e-06	6.42e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—TP53—skin cancer	3.53e-06	5.71e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—HRAS—skin cancer	3.38e-06	5.46e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—IL6—skin cancer	3.23e-06	5.23e-05	CbGpPWpGaD
